PRESCIENT THERAPEUTICS LIMITED — Director's Dealing 2016

Jun 30, 2016

Appendix 3Y Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity Prescient Therapeutics Limited ABN 56 006 569 106

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Paul Hopper
Date of last notice	8 December 2015

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or indirect interest	Direct and Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Deborah Anne Coleman (a related party of Mr Hopper) Moreglade Pty Ltd (a controlled entity of Mr Hopper) Kilinwata Investments Pty Ltd (a controlled entity of Mr Hopper) Alexandra Jane Hopper (a related party of Mr Hopper) Horatia Isabelle Hopper (a related party of Mr Hopper) India Lucy Hopper (a related party of Mr Hopper) Scarlett Augusta Wiseman Hopper (a related party of Mr Hopper)
Date of change	30 June 2016

• See chapter 19 for defined terms.

01/01/2011 Appendix 3Y Page 1

Appendix 3Y Change of Director’s Interest Notice

No. of securities held prior to change Paul Edward Alexander Hopper Deborah Anne Coleman (a related party of Mr Hopper) Moreglade Pty Ltd (a controlled entity of Mr Hopper) Kilinwata Investments Pty Ltd (a controlled entity of Mr Hopper) Alexandra Jane Hopper (a related party of Mr Hopper) Horatia Isabelle Hopper (a related party of Mr Hopper) India Lucy Hopper (a related party of Mr Hopper) Scarlett Augusta Wiseman Hopper (a related party of Mr Hopper)	1,038,137 Fully paid ordinary shares 2,216,667 Fully paid ordinary shares 2,333,334 Fully paid ordinary shares 3,438,334 Fully paid ordinary shares 33,334 Fully paid ordinary shares 33,334 Fully paid ordinary shares 33,334 Fully paid ordinary shares 33,334 Fully paid ordinary shares
Class	1. Fully paid ordinary shares 2. Listed options exercisable at $0.18 (18 cents) per option on or before 30 June 2018.
Number acquired Kilinwata Investments Pty Ltd	1. 44,444 Fully paid ordinary shares 2. 22,222 Listed Options
Number disposed	Nil
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	1. $4,000 2. Nil

• See chapter 19 for defined terms.

Appendix 3Y Page 2

01/01/2011

Appendix 3Y Change of Director’s Interest Notice

No. of securities held after change Paul Edward Alexander Hopper Deborah Anne Coleman (a related party of Mr Hopper) Moreglade Pty Ltd (a controlled entity of Mr Hopper) Kilinwata Investments Pty Ltd (a controlled entity of Mr Hopper) Alexandra Jane Hopper (a related party of Mr Hopper) Horatia Isabelle Hopper (a related party of Mr Hopper) India Lucy Hopper (a related party of Mr Hopper) Scarlett Augusta Wiseman Hopper (a related party of Mr Hopper)

1,038,137 Fully paid ordinary shares 2,216,667 Fully paid ordinary shares 2,333,334 Fully paid ordinary shares 3,482,778 Fully paid ordinary shares 22,222 Listed Options 33,334 Fully paid ordinary shares 33,334 Fully paid ordinary shares 33,334 Fully paid ordinary shares 33,334 Fully paid ordinary shares

Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back

Participation in Pro rata Entitlement offer dated 3 June 2016.

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A

• See chapter 19 for defined terms.

01/01/2011 Appendix 3Y Page 3

Appendix 3Y Change of Director’s Interest Notice

Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 –[+] Closed period

Part 3 –+Closed period
Were the interests in the securities or contracts detailed above traded during a+closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

• See chapter 19 for defined terms.

Appendix 3Y Page 4

01/01/2011

Appendix 3Y Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity Prescient Therapeutics Limited ABN 56 006 569 106

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Steven Lee Yatomi-Clarke
Date of last notice	23 November 2015

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or indirect interest	Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Arrow Wealth Ltd (a controlled entity of Mr Yatomi-Clarke) Novetera Pty Ltd (a controlled entity of Mr Yatomi-Clarke) Alexandra Elizabeth Yatomi-Clarke
Date of change	30 June 2016
No. of securities held prior to change	2,254,412 Fully paid ordinary shares 200,000 unlisted options
Class	1. Fully paid ordinary shares 2. Listed options exercisable at $0.18 (18 cents) per option on or before 30 June 2018.
Number acquired	1. 140,000 Fully paid ordinary shares 2. 70,000 Listed options
Number disposed	Nil

• See chapter 19 for defined terms.

01/01/2011 Appendix 3Y Page 1

Appendix 3Y Change of Director’s Interest Notice

Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	1. $12,600 2. Nil
No. of securities held after change	2,394,412 Fully paid ordinary shares 70,000 Listed Options 200,000 Unlisted options
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Participation in Pro rata Entitlement offer dated 3 June 2016.

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 –[+] Closed period

Were the interests in the securities or contracts detailed No above traded during a[+] closed period where prior written clearance was required? If so, was prior written clearance provided to allow the trade N/A to proceed during this period? If prior written clearance was provided, on what date was this N/A provided?

• See chapter 19 for defined terms.

Appendix 3Y Page 2

01/01/2011